目的 探討鹽酸小檗堿聯(lián)合西格列汀治療肥胖2型糖尿病的臨床療效。方法 選取2014年8月—2015年8月在武安市第一人民醫(yī)院內(nèi)分泌科接受治療的肥胖2型糖尿病患者96例為研究對象，按治療方案的差別分為對照組和治療組，每組各48例。對照組口服磷酸西格列汀片，100 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服鹽酸小檗堿片，0.3 g/次，3次/d，餐前口服。兩組患者均連續(xù)治療12周。觀察兩組的臨床療效，比較兩組患者的血糖指標和炎癥指標。結(jié)果 治療后，對照組和治療組的總有效率分別為83.33%、95.83%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的空腹血糖（FPG）、餐后2 h血糖及糖化血紅蛋白（HbA1c）均明顯降低，同組治療前后差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的C-反應(yīng)蛋白（CRP）、白細胞介素-6（IL-6）、內(nèi)皮素-1（ET-1）及血栓素2（TXB2）均顯著下降，而前列腺素Fla（PGFla）、一氧化氮（NO）均顯著上升，同組治療前后差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 鹽酸小檗堿聯(lián)合西格列汀治療肥胖2型糖尿病具有較好的臨床療效，能明顯降低患者血糖，改善炎癥指標，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of berberine hydrochloride combined with sitagliptin in treatment of diabesity type 2 diabetes mellitus. Methods Patients (96 cases) with diabesity type 2 diabetes mellitus in Department of Endocrinology of Wu'an First People's Hospital from August 2014 to August 2015 were enrolled in this study. According to the different treatment plans, patients were divided into the control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Berberine Hydrochloride Tablets on the basis of the control group, 0.3 g/time, three times daily. After treatment, the efficacies were evaluated, and blood glucose indexes and inflammation indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.83%, respectively, and there was difference between two groups (P<0.05). After treatment, HbA1c, 2hPG, and FPG in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). The observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, CRP, IL-6, TXB2, and ET-1 in two groups were significantly decreased, but PGFla and NO in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). The observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Berberine hydrochloride combined with sitagliptin has the curative effect in treatment of diabesity type 2 diabetes mellitus, can significantly reduce blood glucose indexes, improve inflammation indexes, which has a certain clinical application value.